Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.81 |
| ▸ | ALOX12 | P18054 | 4/20 | 0.81 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.81 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.81 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.81 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.81 |
| ▸ | HPGD | P15428 | 1/20 | 0.81 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.56 |
| ▸ | HTT | P42858 | 3/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 5/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | PNLIP | P16233 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL526059 | 0.88 | MAPT (0.63) | ALDH1A1ALOX12CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL27517394 | 0.86 | MAPT (0.61) | ALDH1A1ALOX12CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL11441885 | 0.84 | ALDH1A1 (0.67) | ALDH1A1ALOX12CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL653550 | 0.83 | ALDH1A1 (0.85) | ALDH1A1ALOX12CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL11541955 | 0.82 | ALDH1A1 (0.54) | ALDH1A1ALOX12CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL20536958 | 0.81 | ALDH1A1 (0.81) | ALDH1A1ALOX12CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL20536976 | 0.81 | ALDH1A1 (0.81) | ALDH1A1ALOX12CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL20536629 | 0.81 | ALDH1A1 (0.81) | ALDH1A1ALOX12CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL20536981 | 0.81 | ALDH1A1 (0.81) | ALDH1A1ALOX12CYP2C9CYP2C19CYP3A4 | |
| SCHEMBL4092732 | 0.81 | NPC1 (0.78) | ALDH1A1ALOX12CYP2C9CYP2C19CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230263167-A1 | METHOD OF PREPARING A BISMUTH SULFIDE PARTICLE CONTAINING ANTIBACTERIAL COMPOSITION | IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY (SA) | 2023-08-24 | — | — | US | disclosed |
| US-11700855-B2 | Method for preventing or reducing growth of a microorganism on a surface | IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY (SA) | 2023-07-18 | — | — | US | disclosed |
| US-20210061670-A1 | METHOD FOR PREVENTING OR REDUCING GROWTH OF A MICROORGANISM ON A SURFACE | IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY (SA) | 2021-03-04 | — | — | US | disclosed |
| US-10934176-B2 | Methods of degrading organic pollutants and preventing or treating microbe using Bi2S3-CdS particles | IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY (SA) | 2021-03-02 | — | — | US | disclosed |
| US-20200102228-A1 | METHODS OF DEGRADING ORGANIC POLLUTANTS AND PREVENTING OR TREATING MICROBE USING Bi2S3-CdS PARTICLES | IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY (SA) | 2020-04-02 | — | — | US | disclosed |
| US-10105687-B1 | Heterostructured Bi2S3—ZnS photocatalysts and methods thereof | IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY (SA) | 2018-10-23 | — | — | US | disclosed |
| US-20160374997-A1 | ANTIBIOTIC COMPOUNDS THAT INHIBIT BACTERIAL PROTEIN SYNTHESIS | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2016-12-29 | — | — | US | disclosed |
| US-20160220510-A1 | ANTIBIOTIC COMPOUNDS THAT INHIBIT BACTERIAL PROTEIN SYNTHESIS | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2016-08-04 | — | — | US | disclosed |
| US-20160220510-A1 | ANTIBIOTIC COMPOUNDS THAT INHIBIT BACTERIAL PROTEIN SYNTHESIS | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2016-08-04 | — | — | US | disclosed |
| US-6562840-B1 | Non-peptidic inhibitors of proteolytic enzymes such as urokinase | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2003-05-13 | — | — | US | disclosed |
| US-6403633-B2 | USEFUL ANTIANGIOGENIC, ANTIARTHRITIC, ANTIINFLAMMATORY, ANTIRESTENOTIC, ANTIINVASIVE, ANTIMETASTIC, ANTIOSTEOPOROTIC, ANTIRETINOPATHIC, CONTRACEPTIVE AND TUMORISTATIC TREATMENT AGENTS | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2002-06-11 | — | — | US | disclosed |
| US-20020037915-A1 | Compounds and compositons for treating C1s-mediated diseases and conditions | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2002-03-28 | — | — | US | disclosed |
| EP-1152759-A2 | METHODS OF TREATING C1s-MEDIATED DISEASES AND CONDITIONS, AND COMPOUNDS AND COMPOSITIONS THEREFOR | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2001-11-14 | — | — | EP | disclosed |
| EP-1150979-A1 | HETEROARYL AMIDINES, METHYLAMIDINES AND GUANIDINES AS PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2001-11-07 | — | — | EP | disclosed |
| US-6291514-B1 | Heteroaryl amidines, methylamidines and guanidines, preparation thereof, and use thereof as protease inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2001-09-18 | — | — | US | disclosed |
| WO-2000047194-A9 | METHODS OF TREATING C1s-MEDIATED DISEASES AND CONDITIONS, AND COMPOUNDS AND COMPOSITIONS THEREFOR | DIMENSIONAL PHARM INC (US) | 2001-05-31 | — | — | WO | disclosed |
| EP-1054886-A1 | HETEROARYL AMIDINES, METHYLAMIDINES AND GUANIDINES AS PROTEASE INHIBITORS, IN PARTICULAR AS UROKINASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2000-11-29 | — | — | EP | disclosed |
| WO-2000047578-A1 | HETEROARYL AMIDINES, METHYLAMIDINES AND GUANIDINES AS PROTEASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2000-08-17 | — | — | WO | disclosed |
| WO-2000047194-A2 | METHODS OF TREATING C1s-MEDIATED DISEASES AND CONDITIONS, AND COMPOUNDS AND COMPOSITIONS THEREFOR | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2000-08-17 | — | — | WO | disclosed |
| WO-1999040088-A1 | HETEROARYL AMIDINES, METHYLAMIDINES AND GUANIDINES AS PROTEASE INHIBITORS, IN PARTICULAR AS UROKINASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 1999-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020037915-A1 | Compounds and compositons for treating C1s-mediated diseases and conditions | C1S, C1R, C9 | ALDH1A1 3467/4885ALOX12 500/4885CYP2C9 2333/4885 |
| US-20160374997-A1 | ANTIBIOTIC COMPOUNDS THAT INHIBIT BACTERIAL PROTEIN SYNTHESIS | AARS1, EPRS1, EEF1G | ALDH1A1 4330/4885ALOX12 2657/4885CYP2C9 3557/4885 |
| US-20160220510-A1 | ANTIBIOTIC COMPOUNDS THAT INHIBIT BACTERIAL PROTEIN SYNTHESIS | AARS1, EPRS1, EEF1G | ALDH1A1 4330/4885ALOX12 2657/4885CYP2C9 3557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.